Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy‐Naïve CLL Patients With the Detectable EBV DNA and High‐Avidity Antibodies Against the EBV Capsid Antigen
Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)
DOI: 10.1155/cjid/3145486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 12.08.2026. Verfasst von Laura Zvejniece und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia, rsu.lv. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Latvijas Zinātnes Padome, Rīgas Stradiņa Universitāte.
Abstract (Originalsprache)
High EBV load in peripheral blood (PB) of untreated patients with chronic lymphocytic leukemia (CLL) has been associated with shorter overall survival. We demonstrated previously that EBV infection of B cells upregulates CCR1 and CCR2. For 54 therapy‐naïve CLL patients of the present study, we analyzed expression of CCR1, CCR2, and CD38 on circulating CD19+CD5+ lymphocytes, determined the EBV load (EBV DNA copy number) and the EBV transcripts (BZLF1, LMP1, LMP2A, and EBNA2) in PB mononuclear cells (PBMCs), and measured levels and avidity of IgG antibodies against the EBV capsid antigen (anti‐EBV‐CA‐IgG). The BZLF1 transcript was determined in one patient; both LMP1 and EBNA2 transcripts were detected in two patients only, and, in these patients, the frequency of CD19+CD5+ lymphocytes that presented CCR1 or CCR2 was elevated by 2.5‐, 4.3‐, and 2.9‐fold and by 2.1‐, 1.2‐, and 2.9‐fold, respectively, relative to the median values in the EBV‐positive group (> 5 EBV DNA copies in 10 5 PBMCs; n = 21). The levels and avidity of anti‐EBV‐CA‐IgG were significantly higher in EBV‐positive patients compared with the EBV‐undetectable group ( p = 0.007 and p = 0.018, respectively). Noteworthy, the high avidity of anti‐EBV‐CA‐IgG, with the relative avidity index (RAI) range 61.0–94.6, was associated in EBV‐positive patients with the increased 2.3‐fold frequency of CCR2 on CD19+CD5+ lymphocytes, compared to patients with the highest avidity (RAI > 95.0; p = 0.006). In patients with the highest anti‐EBV‐CA‐IgG avidity (RAI > 95.0; n = 13), indicative of the high rate of antigen presentation and a recent lytic viral reactivation, the frequency of the CCR2‐presenting CD19+CD5+ PB lymphocytes was 1.7‐fold lower than the median value of all high‐avidity patients ( n = 31; p = 0.032). We hypothesize that CCR2 directs the migration of leukemic lymphocytes from circulation into ligand‐rich lymphoid organs, thereby underlying EBV’s contribution to CLL progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia, rsu.lv.
- Clinic of Hematology, Riga East University Hospital, Riga, Latvia.
- Department of Internal Diseases, Riga Stradins University, Riga, Latvia, rsu.lv.
- Latvian Biomedical Research and Study Centre, Riga, Latvia, lu.lv.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden, ki.se.
- Laboratory of Molecular Mechanisms of Cell Transformation, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine, Kyiv, Ukraine.
ORCID-Profile: Svetlana Kozireva, Mariia Nazarenko, Alla Rivkina, Ainars Leonciks, Modra Murovska, Elena Kashuba, Irina Kholodnyuk
Förderung
- Latvijas Zinātnes Padome
- Rīgas Stradiņa Universitāte
Zitieren
APA
Zvejniece, L., Kozireva, S., Nazarenko, M., Kornilova, O., Rivkina, A., Lejniece, S., Leonciks, A., Murovska, M., Kashuba, E., & Kholodnyuk, I. (2026). Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy‐Naïve CLL Patients With the Detectable EBV DNA and High‐Avidity Antibodies Against the EBV Capsid Antigen. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/3145486
Vancouver
Zvejniece L, Kozireva S, Nazarenko M, Kornilova O, Rivkina A, Lejniece S, et al. Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy‐Naïve CLL Patients With the Detectable EBV DNA and High‐Avidity Antibodies Against the EBV Capsid Antigen. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/3145486
BibTeX
@article{Zvejniece2026,
author = {Zvejniece, Laura and Kozireva, Svetlana and Nazarenko, Mariia and Kornilova, Olga and Rivkina, Alla and Lejniece, Sandra and Leonciks, Ainars and Murovska, Modra and Kashuba, Elena and Kholodnyuk, Irina},
title = {Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy‐Naïve CLL Patients With the Detectable EBV DNA and High‐Avidity Antibodies Against the EBV Capsid Antigen},
journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjid/3145486}
}
EUVIMED